NYSE:BIO - Bio-Rad Laboratories Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $270.34 +8.92 (+3.41 %) (As of 02/15/2019 04:00 PM ET)Previous Close$261.42Today's Range$262.38 - $270.4952-Week Range$220.05 - $345.15Volume268,800 shsAverage Volume240,578 shsMarket Capitalization$8.10 billionP/E Ratio65.94Dividend YieldN/ABeta1.21 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Receive BIO News and Ratings via Email Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNYSE:BIO Previous Symbol CUSIP09057220 Webwww.bio-rad.com Phone510-724-7000Debt Debt-to-Equity Ratio0.09 Current Ratio4.49 Quick Ratio3.16Price-To-Earnings Trailing P/E Ratio65.94 Forward P/E Ratio49.42 P/E Growth2.57 Sales & Book Value Annual Sales$2.16 billion Price / Sales3.75 Cash Flow$4.2728 per share Price / Cash Flow63.27 Book Value$98.38 per share Price / Book2.75Profitability EPS (Most Recent Fiscal Year)$4.10 Net Income$122.24 million Net Margins55.13% Return on Equity3.72% Return on Assets2.67%Miscellaneous Employees3,270 Outstanding Shares29,961,000Market Cap$8.10 billion OptionableOptionable Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions What is Bio-Rad Laboratories' stock symbol? Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO." How will Bio-Rad Laboratories' stock buyback program work? Bio-Rad Laboratories declared that its board has initiated a stock repurchase plan on Wednesday, November 29th 2017, which permits the company to repurchase $250,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued. How were Bio-Rad Laboratories' earnings last quarter? Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its earnings results on Thursday, November, 1st. The medical research company reported $0.91 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.16 by $0.25. The medical research company earned $545.10 million during the quarter, compared to the consensus estimate of $541.23 million. Bio-Rad Laboratories had a net margin of 55.13% and a return on equity of 3.72%. The company's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.91 earnings per share. View Bio-Rad Laboratories' Earnings History. When is Bio-Rad Laboratories' next earnings date? Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Bio-Rad Laboratories. What price target have analysts set for BIO? 7 equities research analysts have issued 12-month price targets for Bio-Rad Laboratories' stock. Their forecasts range from $290.00 to $420.00. On average, they expect Bio-Rad Laboratories' stock price to reach $339.1667 in the next twelve months. This suggests a possible upside of 25.5% from the stock's current price. View Analyst Price Targets for Bio-Rad Laboratories. What is the consensus analysts' recommendation for Bio-Rad Laboratories? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bio-Rad Laboratories. What are Wall Street analysts saying about Bio-Rad Laboratories stock? Here are some recent quotes from research analysts about Bio-Rad Laboratories stock: 1. According to Zacks Investment Research, "Bio-Rad’s declining gross margin is a concern. Challenges associated with successful implementation of the global ERP system remain an overhang. Further, Bio-Rad is exposed to risks associated with a weaker global economy and lower reimbursement rates. However, constant currency sales growth at the Clinical Diagnostics segment was impressive. The company also saw strong growth in the Life Sciences segment and cell biology, Digital PCR and food safety product lines. In addition, solid revenue growth in geographies like North America, China and Asia Pacific buoys optimism. We are also upbeat about the company’s recent 510(k) clearance from the FDA for the IH-Reader 24. Overall, Bio-Rad has been underperforming its industry over the past year." (1/3/2019) 2. Jefferies Financial Group Inc analysts commented, "We see substantial hidden value in BIO’s droplet digital PCR (ddPCR) franchise that is under-appreciated by investors." (9/24/2018) Has Bio-Rad Laboratories been receiving favorable news coverage? Media coverage about BIO stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bio-Rad Laboratories earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. Who are some of Bio-Rad Laboratories' key competitors? Some companies that are related to Bio-Rad Laboratories include Agilent Technologies (A), Waters (WAT), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO.B), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO) and HTG Molecular Diagnostics (HTGM). Who are Bio-Rad Laboratories' key executives? Bio-Rad Laboratories' management team includes the folowing people: Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 69)Ms. Christine A. Tsingos, Exec. VP & CFO (Age 60)Mr. John Goetz, Consultant (Age 69)Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 63)Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 57) Who are Bio-Rad Laboratories' major shareholders? Bio-Rad Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.46%), Atlanta Capital Management Co. L L C (2.50%), Acadian Asset Management LLC (2.07%), Levin Capital Strategies L.P. (1.90%), Millennium Management LLC (1.33%) and Westfield Capital Management Co. LP (1.26%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Institutional Ownership Trends for Bio-Rad Laboratories. Which major investors are selling Bio-Rad Laboratories stock? BIO stock was sold by a variety of institutional investors in the last quarter, including Atlanta Capital Management Co. L L C, Assenagon Asset Management S.A., Acadian Asset Management LLC, Prudential Financial Inc., Columbus Circle Investors, Monarch Partners Asset Management LLC, Dorsey Wright & Associates and State of Tennessee Treasury Department. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Annette Tumolo, Christine A Tsingos, James R Stark and Michael Crowley. View Insider Buying and Selling for Bio-Rad Laboratories. Which major investors are buying Bio-Rad Laboratories stock? BIO stock was purchased by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Tower House Partners LLP, First Trust Advisors LP, Intermede Investment Partners Ltd, BlackRock Inc., Polar Capital LLP, Barclays PLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Bio-Rad Laboratories. How do I buy shares of Bio-Rad Laboratories? Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Bio-Rad Laboratories' stock price today? One share of BIO stock can currently be purchased for approximately $270.34. How big of a company is Bio-Rad Laboratories? Bio-Rad Laboratories has a market capitalization of $8.10 billion and generates $2.16 billion in revenue each year. The medical research company earns $122.24 million in net income (profit) each year or $4.10 on an earnings per share basis. Bio-Rad Laboratories employs 3,270 workers across the globe. What is Bio-Rad Laboratories' official website? The official website for Bio-Rad Laboratories is http://www.bio-rad.com. How can I contact Bio-Rad Laboratories? Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DR, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected] MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 271 (Vote Outperform)Underperform Votes: 271 (Vote Underperform)Total Votes: 542MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2019 by MarketBeat.com StaffFeatured Article: What is a Reverse Stock Split?